Philip Morris jumps as strong Q1 outlook and FDA IQOS reauthorization lift sentiment
Philip Morris International shares rose about 3% on Monday, May 4, 2026, as investors continued to reprice the stock after strong Q1 results and a higher 2026 adjusted EPS outlook. The move also follows a recent U.S. FDA reauthorization allowing IQOS and HEETS to continue being marketed with modified-risk status.
1. What’s happening in PM shares
Philip Morris International (PM) traded sharply higher on Monday, May 4, 2026, outperforming in a move that lines up with a post-earnings repricing rather than a single headline. The stock has been supported by momentum from its late-April quarterly update and renewed optimism around the company’s smoke-free strategy, which has been the key driver of earnings growth and valuation expansion in recent quarters. (pmi.com)
2. The key driver: Q1 beat and higher 2026 adjusted EPS view
PM’s latest quarterly report showed strong year-over-year growth, with adjusted diluted EPS of $1.96 and net revenues around $10.15 billion, as smoke-free products continued to scale and pricing/mix supported margins. Alongside the quarter, PM updated its 2026 full-year adjusted diluted EPS forecast for currency effects, reinforcing investor confidence in the 2026 earnings path and cash-flow durability. (pmi.com)
3. Additional tailwind: FDA reauthorization for IQOS modified-risk marketing
Sentiment has also been buoyed by the U.S. FDA’s reauthorization of IQOS device versions and certain HEETS consumables under the Modified Risk Tobacco Product framework. The reauthorization helps protect the regulatory footing for IQOS marketing in the U.S., a point investors treat as strategically important even though PM’s business remains predominantly international. (nasdaq.com)
4. What to watch next
Investors will be watching for follow-through in smoke-free volume growth and margin performance, plus any incremental updates on U.S. commercialization and regulatory timelines that could change the medium-term earnings cadence. With PM now trading at an elevated valuation versus its long-run history, incremental upside may depend on continued execution in smoke-free products and any further upward revisions to 2026–2027 expectations. (stockanalysis.com)